Juhász-Nagy A - Search Results

1

Changes of endothelin-1 and big endothelin-1 levels and action potential duration during myocardial ischemia-reperfusion in dogs with and without ventricular fibrillation.

Vágó H, Soós P, Zima E, Gellér L, Keltai K, Róka A, Kékesi V, Juhász-Nagy A, Merkely B. Vágó H, et al. Among authors: juhasz nagy a. J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S376-9. J Cardiovasc Pharmacol. 2004. PMID: 15838324

2

Endothelin-1-induced elevations in purine metabolite concentrations -- autoregulatory protection in the canine pericardium?

Zima E, Kékesi V, Nagy A, Losonczi L, Toma I, Soós P, Barát E, Huszár E, Merkely B, Horkay F, Juhász-Nagy A. Zima E, et al. Clin Sci (Lond). 2002 Aug;103 Suppl 48:202S-205S. doi: 10.1042/CS103S202S. Clin Sci (Lond). 2002. PMID: 12193086

3

Expressed monophasic action potential alternans before the onset of ventricular arrhythmias induced by intracoronary bolus administration of endothelin-1 in dogs.

Merkely B, Vágó H, Kiss O, Zima E, Szücs G, Gellér L, Juhász-Nagy A. Merkely B, et al. Clin Sci (Lond). 2002 Aug;103 Suppl 48:219S-222S. doi: 10.1042/CS103S219S. Clin Sci (Lond). 2002. PMID: 12193090

4

The ET(A) receptor antagonist LU 135252 has no electrophysiological or anti-arrhythmic effects during myocardial ischaemia/reperfusion in dogs.

Vágó H, Soós P, Zima E, Gellér L, Kékesi V, Andrási T, Szabó T, Juhász-Nagy A, Merkely B. Vágó H, et al. Clin Sci (Lond). 2002 Aug;103 Suppl 48:223S-227S. doi: 10.1042/CS103S223S. Clin Sci (Lond). 2002. PMID: 12193091

5

Intracoronary endothelin-1 infusion combined with systemic isoproterenol treatment: antagonistic arrhythmogenic effects.

Kiss O, Zima E, Soós P, Kékesi V, Juhász-Nagy A, Merkely B. Kiss O, et al. Among authors: juhasz nagy a. Life Sci. 2004 Jun 18;75(5):537-48. doi: 10.1016/j.lfs.2003.11.033. Life Sci. 2004. PMID: 15158364

6

Endothelin gene expression during ischemia and reperfusion.

Keltai K, Vágó H, Zsáry A, Karádi I, Kékesi V, Juhász-Nagy A, Merkely B. Keltai K, et al. Among authors: juhasz nagy a. J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S198-201. doi: 10.1097/01.fjc.0000166238.64701.a4. J Cardiovasc Pharmacol. 2004. PMID: 15838278

7

Effects of intrapericardially administered endothelin-1 on pericardial natriuretic peptide concentrations of the in situ dog heart.

Toma I, Nagy A, Jánosi C, Rusvai M, Juhász-Nagy A, Kékesi V. Toma I, et al. Among authors: juhasz nagy a. J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S231-3. doi: 10.1097/01.fjc.0000166254.04605.ad. J Cardiovasc Pharmacol. 2004. PMID: 15838287

8

Nitrogen oxide blockade does not aggravate the endothelin-1-induced myocardial ischemia and release of purine metabolites from the dog heart.

Zima E, Kékesi V, Nagy A, Barát E, Huszár E, Toma I, Merkely B, Juhász-Nagy A. Zima E, et al. Among authors: juhasz nagy a. J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S313-7. doi: 10.1097/01.fjc.0000166272.40044.d7. J Cardiovasc Pharmacol. 2004. PMID: 15838309

9

Ventricular tachycardias induced by intracoronary administration of endothelin-1 in dogs.

Tóth M, Solti F, Merkely B, Kékesi V, Horkay F, Szokodi I, Juhász-Nagy A. Tóth M, et al. J Cardiovasc Pharmacol. 1995;26 Suppl 3:S153-5. J Cardiovasc Pharmacol. 1995. PMID: 8587349

10

Verapamil reduces the arrhythmogenic effect of endothelin.

Solti F, Tóth M, Merkely B, Kékesi V, Gellér L, Szokodi I, Horkay F, Juhász-Nagy A. Solti F, et al. J Cardiovasc Pharmacol. 1998;31 Suppl 1:S386-7. doi: 10.1097/00005344-199800001-00110. J Cardiovasc Pharmacol. 1998. PMID: 9595491

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

108 results

Search Page

Filters